Journal of Clinical Oncology, Vol 23, No 26 (September 10), 2005: pp. 6358-6363
© 2005 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2005.26.856
Molecular Pathogenesis of Follicular Lymphoma: A Cross Talk of Genetic and Immunologic Factors
Daphne de Jong
From the Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands
Address reprint requests to Daphne de Jong, Department of Pathology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands; e-mail: d.d.jong{at}nki.nl.
Follicular lymphoma (FL) is the second most frequent type of non-Hodgkin's lymphoma in adults. The disease is characterized by an indolent course with frequent relapses. Ultimately, resistance to chemotherapy or transformation to a more aggressive phase of the disease in the form of diffuse large B-cell lymphoma develops, and patients die as a result of their disease. Median survival is 8 to 10 years. The range is very wide, however, with patients surviving for more than 15 years and 10% to 15% of the patients who run a rapidly fatal course and die within 3 years after diagnosis. The translocation t(14;18) is the basic molecular defect in FL and results in protection from apoptosis by aberrant overexpression of bcl-2 protein. Accumulation of genomic alterations and clonal selection account for subsequent progression and transformation. Recently, the role of the immunologic microenvironment of FL in determining clinical behavior and prognosis has been substantiated. Combined genetic and immunologic data may now support a model for the development of FL as a disease of functional B cells in which specific molecular alterations infer intrinsic growth properties of the tumor cells as well as dictate a specific functional cross talk with the immunologic regulatory network resulting in extrinsic growth support. These insights may lead to improvement of risk stratification, but most importantly will provide tools for developing new targets and strategies for treatment.
Author's disclosures of potential conflicts of interest are found at the end of this article.
This article has been cited by other articles:

|
 |

|
 |
 
J.-J. Goval, C. Thielen, C. Bourguignon, R. Greimers, E. Dejardin, Y. S. Choi, J. Boniver, and L. de Leval
The prevention of spontaneous apoptosis of follicular lymphoma B cells by a follicular dendritic cell line: involvement of caspase-3, caspase-8 and c-FLIP
Haematologica,
August 1, 2008;
93(8):
1169 - 1177.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. P. Piccaluga, A. Califano, U. Klein, C. Agostinelli, B. Bellosillo, E. Gimeno, S. Serrano, F. Sole, Y. Zang, B. Falini, et al.
Gene expression analysis provides a potential rationale for revising the histological grading of follicular lymphomas
Haematologica,
July 1, 2008;
93(7):
1033 - 1038.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. C.-H. Chiu, Q. Lan, B. J. Dave, A. Blair, S. H. Zahm, and D. D. Weisenburger
The Utility of t(14;18) in Understanding Risk Factors for Non-Hodgkin Lymphoma
J Natl Cancer Inst Monographs,
July 1, 2008;
2008(39):
69 - 73.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Mittal, N. A. Marshall, L. Duncan, D. J. Culligan, R. N. Barker, and M. A. Vickers
Local and systemic induction of CD4+CD25+ regulatory T-cell population by non-Hodgkin lymphoma
Blood,
June 1, 2008;
111(11):
5359 - 5370.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Taskinen, M.-L. Karjalainen-Lindsberg, and S. Leppa
Prognostic influence of tumor-infiltrating mast cells in patients with follicular lymphoma treated with rituximab and CHOP
Blood,
May 1, 2008;
111(9):
4664 - 4667.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Tzankov, C. Meier, P. Hirschmann, P. Went, S. A. Pileri, and S. Dirnhofer
Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma
Haematologica,
February 1, 2008;
93(2):
193 - 200.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Knoops, R. Haas, S. de Kemp, D. Majoor, A. Broeks, E. Eldering, J. P. de Boer, M. Verheij, C. van Ostrom, A. de Vries, et al.
In vivo p53 response and immune reaction underlie highly effective low-dose radiotherapy in follicular lymphoma
Blood,
August 15, 2007;
110(4):
1116 - 1122.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. R. Cerhan, S. Wang, M. J. Maurer, S. M. Ansell, S. M. Geyer, W. Cozen, L. M. Morton, S. Davis, R. K. Severson, N. Rothman, et al.
Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival
Blood,
June 15, 2007;
109(12):
5439 - 5446.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. L. Scott, J. Gil, E. Hernando, J. Teruya-Feldstein, M. Narita, D. Martinez, T. Visakorpi, D. Mu, C. Cordon-Cardo, G. Peters, et al.
Role of the chromobox protein CBX7 in lymphomagenesis
PNAS,
March 27, 2007;
104(13):
5389 - 5394.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. C.-H. Chiu, B. J. Dave, A. Blair, S. M. Gapstur, J. S. Chmiel, A. J. Fought, S. H. Zahm, and D. D. Weisenburger
Cigarette Smoking, Familial Hematopoietic Cancer, Hair Dye Use, and Risk of t(14;18)-defined Subtypes of Non-Hodgkin's Lymphoma
Am. J. Epidemiol.,
March 15, 2007;
165(6):
652 - 659.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. M. Glas, L. Knoops, L. Delahaye, M. J. Kersten, R. E. Kibbelaar, L. A. Wessels, R. van Laar, J. H. J.M. van Krieken, J. W. Baars, J. Raemaekers, et al.
Gene-Expression and Immunohistochemical Study of Specific T-Cell Subsets and Accessory Cell Types in the Transformation and Prognosis of Follicular Lymphoma
J. Clin. Oncol.,
February 1, 2007;
25(4):
390 - 398.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. J. Giles
Syk-driven mTOR in lymphoma-complimentary targets?
Blood,
December 15, 2006;
108(13):
3957 - 3958.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Alvaro, M. Lejeune, M.-T. Salvado, C. Lopez, J. Jaen, R. Bosch, and L. E. Pons
Immunohistochemical Patterns of Reactive Microenvironment Are Associated With Clinicobiologic Behavior in Follicular Lymphoma Patients
J. Clin. Oncol.,
December 1, 2006;
24(34):
5350 - 5357.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Carreras, A. Lopez-Guillermo, B. C. Fox, L. Colomo, A. Martinez, G. Roncador, E. Montserrat, E. Campo, and A. H. Banham
High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma
Blood,
November 1, 2006;
108(9):
2957 - 2964.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z.-Z. Yang, A. J. Novak, M. J. Stenson, T. E. Witzig, and S. M. Ansell
Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma
Blood,
May 1, 2006;
107(9):
3639 - 3646.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. H. Sehn
Optimal Use of Prognostic Factors in Non-Hodgkin Lymphoma
Hematology,
January 1, 2006;
2006(1):
295 - 302.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|